[{"data":1,"prerenderedAt":180},["ShallowReactive",2],{"drug-olaparib":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":43,"contraindications":76,"warnings":77,"renal":85,"monitoring":86,"interactions":87,"review":88,"examples":91,"atc":96,"iran":98,"usApproval":114,"links":120,"populations":136},"olaparib",1,{"fa":7,"en":8},"اولاپاریب","Olaparib","antineoplastic-immunomodulating",{"fa":11,"en":12},"مهارکننده PARP","PARP inhibitor",[14],{"name":15,"market":16},"Lynparza","US",[18,19,7],"lynparza","لینپارزا",[21,35],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-100","tablet","oral","100 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},100,"mg",false,[16],[32],{"source":33,"section":34},"fda-lynparza","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"tab-150","150 mg tablet",{"amount":39,"unit":28,"perUnit":23,"scored":29},150,[16],[42],{"source":33,"section":34},[44],{"id":45,"disease":46,"label":47,"population":50,"type":54,"unit":28,"dose":55,"refs":58,"notes":61},"ovary","ovarian-cancer",{"fa":48,"en":49},"سرطان تخمدان، پستان، پانکراس و پروستات با جهش BRCA\u002FHRR — ۳۰۰ mg دو بار در روز","BRCA\u002FHRR-mutated ovarian, breast, pancreatic and prostate cancer — 300 mg twice daily",{"minAge":51},{"value":52,"unit":53},18,"year","fixed",{"perDose":56,"dosesPerDay":57},300,2,[59],{"source":33,"section":60},"2.2",[62,68],{"text":63,"refs":66},{"fa":64,"en":65},"فقط زیر نظر متخصص انکولوژی؛ ادامه تا پیشرفت بیماری یا سمیت غیرقابل‌قبول. تنظیم دوز برای عوارض و تداخل‌ها طبق برچسب.","Only under an oncologist; continue until progression or unacceptable toxicity. Dose adjustments for toxicity and interactions per label.",[67],{"source":33,"section":60},{"text":69,"refs":72},{"fa":70,"en":71},"قرص کامل بلعیده شود. پروستات: همراه آنالوگ GnRH یا پس از اورکیدکتومی. نارسایی متوسط کلیه: کاهش دوز.","Swallow whole. Prostate: with a GnRH analogue or after orchiectomy. Moderate renal impairment: reduce dose.",[73,74],{"source":33,"section":60},{"source":33,"section":75},"2",[],[78],{"text":79,"refs":82},{"fa":80,"en":81},"MDS\u002FAML؛ پنومونیت؛ ترومبوآمبولی وریدی؛ سمیت کبدی؛ سمیت جنینی.","MDS\u002FAML; pneumonitis; venous thromboembolism; hepatotoxicity; embryo-fetal toxicity.",[83],{"source":33,"section":84},"5",[],[],[],{"status":89,"reviewer":90,"date":90},"unverified",null,[92],{"regimen":45,"formulation":36,"input":93,"expect":95},{"ageYears":94,"weightKg":94},60,{"perDose":56,"tabletsPerDoseRounded":57},[97],"L01XK01",{"status":99,"forms":100,"refs":109},"registered",[101,105],{"code":102,"en":103,"fa":104},"52428","OLAPARIB CAPSULE ORAL 50 mg","کپسول ولاپاریب ۵۰ میلی‌گرم",{"code":106,"en":107,"fa":108},"52728","OLAPARIB TABLET ORAL 150 mg","قرص ولاپاریب ۱۵۰ میلی‌گرم",[110],{"source":111,"section":112,"url":113},"darooyab-generic","G-5516\u002FOlaparib","https:\u002F\u002Fwww.darooyab.ir\u002FG-5516\u002FOlaparib",{"kind":115,"refs":116,"id":119},"NDA",[117],{"source":33,"section":118},"SPL approval \u002F marketing category","NDA208558",[121,124,128,131,134],{"kind":122,"url":123,"label":119},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=208558",{"kind":125,"url":126,"label":127},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa","FDA Lynparza",{"kind":129,"url":130,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa614060.html",{"kind":132,"url":133,"label":97},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=L01XK01",{"kind":135,"url":113,"label":8},"darooyab",{"pregnancy":137,"lactation":146,"pediatric":154,"geriatric":163,"reproductive":172},{"level":138,"text":139,"quote":142,"refs":143},"avoid",{"fa":140,"en":141},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Risk Summary Based on findings in animals and its mechanism of action [see Clinical Pharmacology (12.1) ] , Lynparza can cause fetal harm when administered to a pregnant woman.",[144],{"source":33,"section":145},"8.1",{"level":138,"text":147,"quote":150,"refs":151},{"fa":148,"en":149},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","Because of the potential for serious adverse reactions in the breastfed infants from Lynparza, advise a lactating woman not to breastfeed during treatment with Lynparza and for one month after receiving the last dose.",[152],{"source":33,"section":153},"8.2",{"level":155,"text":156,"quote":159,"refs":160},"caution",{"fa":157,"en":158},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Safety and effectiveness of Lynparza have not been established in pediatric patients.",[161],{"source":33,"section":162},"8.4",{"level":164,"text":165,"quote":168,"refs":169},"ok",{"fa":166,"en":167},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in the safety or effectiveness of Lynparza were observed between these patients and younger patients.",[170],{"source":33,"section":171},"8.5",{"level":155,"text":173,"quote":176,"refs":177},{"fa":174,"en":175},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Contraception Females Advise females of reproductive potential to use effective contraception during treatment with Lynparza and for 6 months following the last dose.",[178],{"source":33,"section":179},"8.3",1792444414502]